Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Jay ParekhKaushal ParikhJoshua E ReussAlex FriedlaenderAlfredo AddeoPublished in: Current oncology reports (2023)
Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC.
Keyphrases
- locally advanced
- rectal cancer
- small cell lung cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- phase ii study
- clinical trial
- advanced non small cell lung cancer
- lymph node
- brain metastases
- machine learning
- phase iii
- double blind
- phase ii
- big data
- epidermal growth factor receptor
- electronic health record
- tyrosine kinase